MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 Patients
COVID-19 Severity analyses host-immune response proteins to accurately determine whether patients infected with SARS-Cov-2 are likely to have a severe outcome
HAIFA, Israel, July 23, 2021 – MeMed, a leader in host response-based solutions, today announces that it has received the CE Mark in Europe for its new disease management solution, MeMed COVID-19 Severity™.
MeMed COVID-19 Severity™, a unique host response signature, measures multiple proteins from a single serum sample and applies machine learning to stratify the risk that a patient with COVID-19 disease is likely to experience severe outcomes.
The test, which runs in 15 minutes on the Company’s point-of-need platform, MeMed Key, aims to help physicians identify who may benefit from escalated care and who may be safely discharged from the hospital and instructed to self-isolate at home.
Eran Eden, MeMed’s co-founder and CEO, said: “I am delighted that we are now able to commercialize a solution to help identify COVID-19 patients at risk of severe outcomes, empowering physicians to manage what is increasingly looking likely to become an endemic situation. MeMed COVID-19 Severity is another exciting step in the company’s long-term vision of harnessing the host-immune response in order to transform the way infections are detected, assessed, and managed, particularly relevant for authorities contemplating preparedness for future pandemics.”
MeMed has recently published the results from a multinational derivation study, demonstrating the signature’s ability to accurately predict severe COVID-19 respiratory failure. The company has completed an additional independent multinational validation study; the results will be revealed in coming months.
Sergey Motov, MD, Professor of Emergency Medicine, Maimonides Medical Center said: “Highly sensitive and accurate diagnostic and prognostic tests are key tools for clinicians. As an ER doctor myself, I am fascinated by the potential for host immune response technologies to help predict patient outcomes. Tools like MeMed COVID-19 Severity are a win-win solution: doctors can assess the likelihood of patients suffering from severe complications, enabling tailored treatments or discharge if the risk of deteriorating is low.”
MeMed COVID-19 Severity will be available in Europe directly from MeMed in our priority countries and through our commercial partner channels in others.
Riwat Lim, Head of Commercial, Europe commented: “We are delighted to have obtained a CE Mark for our new MeMed COVID-19 Severity product. This represents an important contribution to tackling a disease that has profoundly affected the lives of people in Europe and around the globe. We are going to deploy this next generation COVID-19 test to help emergency physicians in Europe better predict disease severity, initiating in countries currently still badly affected by new cases.”
Our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. For additional information on MeMed, please visit http://www.me-med.com.
About MeMed COVID-19 Severity
MeMed COVID-19 Severity is a predictive and actionable patient management tool. It is designed to address COVID-19 disease complexity by encompassing markers from distinct biological pathways. The test enables physicians to detect early the likelihood of deterioration in patients affected by COVID-19 and provides a leap forward in COVID-19 patient management. The tool is easy to use and provides easy to interpret results in under 15 minutes from a small serum sample.
Consilium Strategic Communications